Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6192449 | Journal of Thoracic Oncology | 2016 | 12 Pages |
Abstract
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hui MD, PhD, Theresa A. MD, PhD, Caicun MD, PhD, David L. MD, PhD, Fred R. MD, PhD,